CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a biopharmaceutical
company developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin peptide receptor system,
announced a presentation of the positive effects of PL8177 on
treating ulcerative colitis in an animal disease model, including
genomic data characterizing the anti-inflammatory effects of
melanocortin agonists. The poster presentation of the efficacy and
cellular and molecular effects of the melanocortin 1 receptor
agonist PL8177 in a rat model of ulcerative colitis will be
presented at the Crohn's and Colitis Congress, being held
virtually, on January 21,
2022.
The data presented showed that orally administered PL8177
improved markers of colitis compared to the vehicle group. Also,
data from colon samples from the DSS rat model showed significantly
lower expression of a gene involved in regulating immune response
in the bowel. These results support the aim of ultimately treating
inflammatory bowel disease in humans. Palatin is planning to
conduct a phase 2 clinical study evaluating PL8177 administered
orally as a treatment for ulcerative colitis later this year.
"The results of this ulcerative colitis study, including data
from cutting edge genomic and proteomic platforms, are a
demonstration of the excellent science our research team is doing,
not only supporting Palatin's development programs, but also
expanding knowledge about how melanocortins regulate inflammation,"
said Carl Spana, Ph.D., CEO and
President of Palatin.
Poster session details:
Session Title: Animal Models: Pre-Clinical Treatment of
Intestinal Inflammation
Session Date: Friday, January 21,
2022
Session Time: 12–1 p.m. EASTERN STANDARD TIME (UTC -5)
Presentation Title: CELLULAR AND MOLECULAR IMPACT OF THE
MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE
(DSS)-INDUCED COLITIS IN RATS
Presentation Time: 12–1 p.m. EASTERN STANDARD TIME (UTC
-5)
The poster is available on Palatin's website at:
www.palatin.com.
About PL8177
PL8177 is a synthetic cyclic heptapeptide with demonstrated
efficacy in animal inflammatory bowel disease models. PL8177
is a potent agonist at the human melanocortin receptor-1 (MC1r),
with sub-nanomolar affinity binding and
EC50 functional values. Palatin data
demonstrates that the oral formulation of PL8177 was protected from
degradation in the stomach and small intestine and delivered to the
large intestine and colon over an extended period. In
addition, orally administered PL8177 had a significant effect on
resolving inflammation in a rat bowel inflammation model.
PL8177 in oral formulations has demonstrated repeated, robust
efficacy in ulcerative colitis disease models. MC1r is found on
epithelial cells and resident macrophages of the colon which are
accessible from the lumen of the colon. Orally administered PL8177
is not systemically absorbed. PL8177 has the potential for
excellent efficacy without safety concerns.
About Ulcerative Colitis
Ulcerative colitis is a chronic disease of the large intestine
(colon), with inflammation and ulcerations that can cause
significant abdominal pain, persistent diarrhea, loss of appetite
and other symptoms. Over 700,000 individuals in the United
States are affected by ulcerative colitis, with over 350,000
diagnosed with moderate-to-severe disease. Existing treatments are
not effective in a large portion of patients with
moderate-to-severe ulcerative colitis, with some severe cases
resulting in surgical removal of the colon.
About Melanocortin Receptor Agonists and Inflammation
The melanocortin receptor ("MCr") system has effects on
inflammation, immune system responses, metabolism, food intake, and
sexual function. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin and natriuretic peptide receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.palatin.com and follow
Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin, such as
statements about clinical trial plans and potential results for
clinical or pre-clinical programs, are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Palatin intends that such forward-looking statements be subject to
the safe harbors created thereby. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that could cause Palatin's actual results to be materially
different from its historical results or from any results expressed
or implied by such forward-looking statements. Palatin's actual
results may differ materially from those discussed in the
forward-looking statements for reasons including, but not limited
to, results of clinical trials, regulatory actions by the FDA and
other regulatory and the need for regulatory approvals, Palatin's
ability to fund development of its technology and establish and
successfully complete clinical trials, the length of time and cost
required to complete clinical trials and submit applications for
regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-announces-presentation-at-the-2022-crohns-and-colitis-congress-301465545.html
SOURCE Palatin Technologies, Inc.